ReviewTranslational psychiatry2026
Role of neural oscillations in depression: highlights on gamma oscillations.
Review in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a prevalent and debilitating psychiatric disorder traditionally conceptualized as monoaminergic dysregulation. Although this view has guided pharmacotherapeutic development for decades, its clinical and mechanistic limitations have spurred research into alternative frameworks, particularly those focusing on network-level dysfunctions. Within this evolving framework, neural oscillations, especially in the frequency of gamma oscillations (30-80 Hz), serve as a critical windowt into the dynamics of the large-scale brain network. Therefore, this review summarizes a substantial body of evidence positing a central role for aberrant gamma oscillations in the pathophysiology of depression. We first synthesize the neurobiological basis of gamma oscillations and critique their crucial relationship with synaptic plasticity, proposing that gamma impairments may underpin key cognitive and affective deficits observed in this disorder. Notably, we critically examine the complex effects of conventional antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and neuromodulation therapies like repetitive transcranial magnetic stimulation (rTMS) and deep brain stimulation (DBS) on gamma oscillations. Finally, we discuss emerging gamma oscillation-targeting therapies like 40 Hz flickering light therapy and future directions. In summary, we conclude that gamma oscillations represent not an epiphenomenon but a fundamental pathophysiological hub and a promising therapeutic target, paving the way for more precise and effective treatments for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.